Immune Pharmaceuticals Announces Exclusive License to a Novel Bispecific Antibody Technology

New technology will allow for the development of innovative drug candidates targeting immune checkpoints NEW YORK, Dec. 28, 2015 /PRNewswire/ — Immune Pharmaceuticals Inc. (NASDAQ:IMNP) (“Immune”) a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, today announced it has entered into an exclusive license with Atlante Biotech SAS, to the patents…